drugset / Trial / NCT01659515
Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
Expanded access
No longer available
U.S. Army Medical Research and Development Command
Meiji Seika Pharma Co., Ltd. · collabUniformed Services University of the Health Sciences · collab
Summary
Arbekacin for the use of infection caused by multidrug-resistant organisms
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arbekacin | Unknown | 5 mg/kg | Intravenous |
| Subject | Arbekacin | Unknown | 7 mg/kg | Intravenous |